Skip to content
ALL Metrics
-
Views
Get PDF
Get XML
Cite
Export
Track
Method Article

Generation of human midbrain organoids from induced pluripotent stem cells

[version 1; peer review: 1 approved, 3 approved with reservations]
PUBLISHED 03 Apr 2019
Author details Author details
OPEN PEER REVIEW
REVIEWER STATUS

Abstract

The development of brain organoids represents a major technological advance in the stem cell field, a novel bridge between traditional 2D cultures and in vivo animal models. In particular, the development of midbrain organoids containing functional dopaminergic neurons producing neuromelanin granules, a by-product of dopamine synthesis, represents a potential new model for Parkinson’s disease. To generate human midbrain organoids, we introduce specific inductive cues, at defined timepoints, during the 3D culture process to drive the stem cells towards a midbrain fate. In this method paper, we describe a standardized protocol to generate human midbrain organoids (hMOs) from induced pluripotent stem cells (iPSCs). This protocol was developed to demonstrate how human iPSCs can be successfully differentiated into numerous, high quality midbrain organoids in one batch. We also describe adaptations for cryosectioning of fixed organoids for subsequent histological analysis.

Keywords

Organoid, midbrain, iPSC, cryosections, neuromelanin, dopaminergic neurons

Background

Parkinson’s disease (PD) is a neurodegenerative disorder, affecting more than 1% of the population over 65 years of age. The majority of cases are idiopathic, while about 10% have been linked to genetic mutations. Classical hallmarks of PD are the loss of dopaminergic (DA) neurons in the substantia nigra pars compacta, accompanied by the presence of neuronal inclusions called “Lewy bodies”. Several cellular pathways have been implicated in PD pathogenesis, including mitochondrial dysfunction13, perturbed neuronal activity4,5 and dysregulated protein homeostasis due to lysosomal, autophagy and proteasomal defects69. However, there is no treatment to halt the progression of the disease. To date, treatment of PD is limited to symptom management. It is therefore necessary to refine the models we use in fundamental research to understand the pathophysiology of PD and to develop more effective therapeutic strategies.

In 2006, Drs. Kazutoshi Takahashi and Shinya Yamanaka described the reprogramming of somatic cells into induced pluripotent stem cells (iPSCs)10. Since their discovery, this technology has opened up many new research avenues, including for PD. With their self-renewal abilities and potential to be differentiated into disease-relevant cells from all three developmental lineages, iPSCs provide a unique tool to study PD within a human neuron, without the difficulties in obtaining neurons from a human brain11. iPSCs can be directly reprogrammed from skin, blood or urine of an individual without raising the ethical concerns previously triggered by the use of fetal stem cells. In 2009, Soldner et al. were the first to describe the generation of an iPSC cell-line from a patient with sporadic PD, and the subsequent differentiation of these cells into dopaminergic (DA) neurons12. Taking advantage of iPSC technology, many studies have started to investigate the pathological mechanisms of PD in iPSC-derived DA neurons from patients, compared to neurons from healthy individuals1333.

Recently, the development of organoids has become a major technological advance in the stem cell field and represents a bridge between traditional 2D cultures and in vivo mouse models. In 2013, Lancaster et al. described a novel 3D model called a cerebral organoid, that recapitulated different areas of the human brain34. Kept in culture, these organoids formed a complex self-organized neuronal tissue composed of a mixed population of neurons, astrocytes and oligodendrocytes. In contrast to neurospheres, the cells were organized in layers that, at early stages, included a ventricular zone composed of progenitors. Neurons within these organoids were functional and had spontaneous electrical activity in networks. Interestingly, brain organoids could be cultured for long periods to obtain morphologically and functionally mature cells, in contrast to neurosphere cultures3437.

Since 2013, different types of brain organoids have been generated based on adaptations of the initial protocol published by Lancaster. Earlier, the protocols involved no external addition of growth factors in the medium, resulting in self-differentiating cells. However, different laboratories now directly drive the stem cells towards specific fates. The key to efficient brain organoid generation is a defined combination of inductive signals and physical factors that drive pluripotent stem cells to form 3D brain organoids. The modulation of these factors gives rise to multiple types of brain organoids that can be used to model neurodevelopmental and neurodegenerative disorders that affect distinct regions within the brain. Protocols now exist for making human cerebral34,38,39, forebrain-like (dorsal and ventral)40,41, cerebellar42, cortical-like (dorsal and ventral)43,44, hippocampal and choroid plexus-like tissue45, midbrain35,36,41, hypothalamic41, pallium and subpallium46 brain organoids.

iPSC-derived human brain organoids recapitulate brain development and can be used to study normal neurodevelopment. Brain organoid development recapitulates the early to mid-fetal development, and the epigenomic signatures of the human foetal brain41,47,48. So far, cerebral organoids have been used to study pathologies including microcephaly34, Zika virus infection4952, and autism spectrum disorders46,53.

Recently, human brain organoids have been used to investigate aspects of neurodegenerative disorders. Two groups generated cerebral organoids from iPSCs of Alzheimer’s disease (AD) patients carrying familial mutations for presenilin 1 or amyloid precursor protein duplication, and successfully recapitulated the aggregation of beta-amyloid protein and tau pathology (hyperphosphorylation and aggregation), the two neuropathological markers of AD, in a human model. Treatment of the 3D cultures with drugs targeting either amyloid-beta aggregation or tau phosphorylation decreased the pathological markers54,55. These promising results demonstrated that human brain organoids represent a relevant model for drug discovery. The development of different types of brain organoids represents a major advance in the stem cell field. In particular, the development of midbrain organoids represents a new drug discovery tool for PD. Two groups published similar protocols to generate the human midbrain organoids, based on specific inductive signals introduced at specific stages in the 3D cultures to drive the stem cells towards a midbrain fate35,36. They showed that the midbrain organoids are composed of functional midbrain neurons producing neuromelanin granules, a by-product of dopamine synthesis. Of the neuronal population, 30% was myelinated due to the presence of oligodendrocytes. Interestingly, Monzel et al., showed the presence of nodes of Ranvier and spontaneous saltatory transmission35,36. Considering the mix of neuronal populations connected within the midbrain organoids, they represent an interesting model to discover new pathological mechanisms involved in PD.

In this paper, we provide a standardized protocol for a robust derivation of iPSCs lines into 3D midbrain organoids. This protocol is an adaptation of the Nature protocol paper initially published by Lancaster in combination with discoveries from Jo et al. and Monzel et al.3436 in order to successfully produce high quality midbrain organoids with a successful midbrain fate generation rate of near 100% per batch. We also describe a cryosectioning protocol that we adapted to produce high-quality histological sections from midbrain organoids, overcoming difficulties resulting from the particular texture of cultured tissue as well as their small size, relative to rodent brains. Taken together, this article extensively explains the methods involved in generating these iPSC-derived organoids and their histological analysis.

Materials

The materials, reagents and equipment listed in this document can be substituted. However, the performance of the protocol may not be the same and may need to be optimized or redeveloped upon significant modifications to the materials and/or methods. It is also important to note that there is a significant lot-to-lot variability for certain reagents. In order to monitor this variability, we recommend a systematic test of new batches.

List of materials, reagents and equipment for 3D midbrain generation

For growing human iPSCs, the quality of reagents is critical. Variability in the quality of any of these materials or in associated manufacturing processes will lead to inconsistent quality, which has been reported to negatively impact human iPSCs cultures. See Table 1 and Table 2.

Table 1. List of media and biochemicals.

ReagentsSupplier/ manufacturerCatalogue number
mTeSRTM1 Basal medium/ mTeSRTM1
5x supplement
STEMCELL Technologies05851/05852
Dulbecco's Modified Eagle Medium/
Nutrient Mixture F-12 (DMEM/F12)
Gibco10-565-018
NeurobasalThermo Fisher21103-049
B27 without vitamin AInvitrogen12587010
GlutamaxGibco35050-061
Minimum Essential Medium- Non-Essential
Amino Acids (MEM-NEAA)
Invitrogen11140050
2-mercaptoethanolGibco21985023
HeparinMillipore SigmaH3149
SB431542Selleck ChemicalsS1067
NogginPeproTech120-10C
CHIR99021Selleck ChemicalsS2924
ROCK inhibitorTocris Bioscience1254
Sonic Hedgehog (SHH)PeproTech100-45
Fibroblast Growth Factor 8 (FGF8)PeproTech100-25
InsulinMillipore SigmaI9278
LamininMillipore SigmaL2020
Penicillin-StreptomycinMillipore SigmaP0781
Brain-derived Neurotrophic Factor (BDNF)PeproTech450-02
Glial cell-derived Neurotrophic Factor
(GDNF)
PeproTech450-10
Ascorbic acidMillipore SigmaA5960
Dibutyryl- cyclic AMP (db-cAMP)Millipore SigmaD0627
AccutaseGibcoA11105-01
Matrigel® reduced growth factorBD Biosciences356230
N2Gibco17504-044
Antibiotics-AntimycoticGibco15240-062

Table 2. List of consumables and equipment.

Consumables and equipmentSupplierCatalogue No.
Cell culture dishes, 10cmThermo Fisher08772E
96 well plates U-bottomed wells ultra low attachmentCorningCLS7007
5ml serological pipettes, wrappedThermo Fisher1367811D
15ml Falcon Conical tubeThermo Fisher352097
50ml Falcon Conical tubeThermo Fisher352098
6 well plates, ultra-low attachmentCorning Co-starCLS3471
10µl ultrafine long tips (Autoclave before use in cell
culture)
Harvard ApparatusDV-P1096-FR
100-250μl non-sterile ultrafine tips, refill package
(autoclave before use in cell culture)
VWR89368-954
100-1250μl non-sterile ultrafine tips, refill package
(autoclave before use in cell culture)
VWR89079-470
Nitrile glove, Small (Box of 100, other sizes available
from XS-XL)
DiamedTECNITE-SPF
Pipette Set, GilsonMandel Scientific
Pipette Aid, DrummondVWR53498-105
25°C incubatorThermo FisherS50909
Centrifuge for 96 well platesEppendorf022625501
Orbital shakerScientific Industries IncSI-M100
Multichannel pipetteGilson
50mL reagent reservoirCorning4870
Box of 1mL cut tips autoclaved
Manual repeater pipetteGilsonF164072
Distritips mini ST for manual repeaterGilsonF164140

Background information on media.

Neuronal induction medium: A cell-permeable, highly potent and selective inhibitor of Rho-associated, coiled-coil containing protein kinase (ROCK) enhances survival of iPSCs when dissociated to single cells and improves embryonic bodies formation56. Midbrain is of ectodermal origin, thus neuroectodermal differentiation towards a floor plate can be induced with the help of dual-SMAD inhibition factors, Noggin and SB431542 and a Wnt pathway activator, CHIR99021 (chemical name: 6- [[2-[[4-(2,4-dichlorophenyl)-5-(5-methyl-1H-imidazol-2-yl)-2-pyrimidinyl]amino]ethyl]amino]-3-pyridinecarbonitrile)57. Complementary to these factors, heparin plays a role in enhancing the activity of Wnt signaling58. 2-mercaptoethanol regulates oxidative stress to maintain cell growth and avoid cell death due to toxicity. Retinoic acid, a metabolite of vitamin A, is a potent caudalizing factor that we exclude from our media to promote midbrain differentiation. See Table 3.

Table 3. Composition of neuronal induction medium.

Final ConcentrationRecipe (50 ml)
DMEM-F12 + Anti /Neurobasal (1:1)25 mL + 25 mL
1:100 N20.5 mL
1:50 B27 without vitamin A1 mL
1% Glutamax0.5 mL
1% MEM-NEAA0.5 mL
2-mercaptoethanol0.175 µL
1 μg/mL Heparin50 µL
10 μM SB43154250 µL
200 ng/mL Noggin50 µL
0.8 μM CHIR9902113.5 µL
10 μM ROCK inhibitor50 µL

Note: DMEM-F12+ Anti is an initial mix of 5 mL of Antibiotics-Antimycotics to 495 mL of DMEM-F12

Midbrain patterning medium: The patterning can be influenced by sonic hedgehog, SHH and fibroblast growth factor FGF8 as they are responsible for guiding the cells towards the mesencephalic fate59. To avoid the dorsal influence on organoids patterning, vitamin B27 without vitamin A is considered appropriate60. See Table 4.

Table 4. Composition of midbrain patterning medium.

Final ConcentrationRecipe (50 ml)
DMEM-F12 + Anti /Neurobasal (1:1)25 mL + 25 mL
1:100 N20.5 mL
1:50 B27 without vitamin A1 mL
1% Glutamax0.5 mL
1% MEM-NEAA0.5 mL
2-mercaptoethanol0.175 µL
1 μg/mL Heparin50 µL
10 μM SB43154250 µL
200 ng/mL Noggin50 µL
0.8 μM CHIR9902113.5 µL
100 ng/mL (or 200ng/mL) SHH25 µL
100 ng/ mL FGF850 µL

Note: DMEM-F12+ Anti is an initial mix of 5 mL of Antibiotics-Antimycotics to 495 mL of DMEM-F12

Tissue Growth Induction Medium: The presence of insulin and laminin promote the growth of tissue embedded. See Table 5.

Table 5. Composition of tissue growth induction medium.

Final ConcentrationRecipe (50 mL)
Neurobasal50 mL
1:100 N20.5 mL
1:50 B27 without vitamin A1 mL
1% Glutamax0.5 mL
1% MEM-NEAA0.5 mL
2-mercaptoethanol0.175 µL
2,5 μg/mL insulin12.5 µL
200 ng/mL laminin8.5 µL
100 ng/mL (or 200 ng/mL) SHH25 µL (or 50 µL)
100 ng/ mL FGF850 µL
Penni/Strep0.05 mL

Final Differentiation Medium: The presence of brain-derived neurotrophic factor (BDNF), is reported to play a potential role in developing cholinergic, dopaminergic, serotonergic and gamma-aminobutyric acid (GABA) ergic neurons, along with promoting the function and survival of other neuronal populations61 The other growth factor, glial cell-derived neurotrophic factor (GDNF) also affects neuronal differentiation, maturation and neurite growth by enhancing myelination. It has also been reported to induce dopaminergic phoneotype62. See Table 6.

Table 6. Composition of final differentiation medium.

Final ConcentrationRecipe (50 ml)
Neurobasal50 mL
1:100 N20.5 mL
1:50 B27 without vitamin A1 mL
1% Glutamax0.5 mL
1% MEM-NEAA0.5 mL
2-mercaptoethanol0.175 µL
10 ng/mL BDNF25 µL
10 ng/mL GDNF25 µL
100 μM ascorbic acid25 µL
125 μM db-cAMP12.5 µL
Penni/Strep0.05 mL

iPSC lines

For growing midbrain organoids from human iPSCs, the quality of iPSCs is critical. Variability in the iPSCs maintenance will negatively impact midbrain organoids generation (section “Protocol description for iPSC culture and maintenance”). The observations provided in this method were generated from two iPSCs lines from healthy individuals, NCRM-1 and XCl-1 (Table 7).

Table 7. Summary of iPSCs used.

iPSC line
name
Supplier
NCRM-1NIH CRM Lonza Contract
https://nimhstemcells.org/crm.html
XCl-1Dr Xianmin Zeng’s laboratory
The Buck Institute for Research on Aging
https://xcell-app-prod.s3-us-west-1.amazonaws.
com/file/spina/attachment/2/69_CNS_iPSC_review_
SCTM.pdf

List of material, reagents and equipment for 3D midbrain histological processing and cryosections

See Table 8.

Table 8. Material for histological sections.

Reagents and equipmentSupplierCatalogue No.
FormaldehydeThermo Scientific28908
Frosted microscope slidesFisher Scientific12-550-15
CryomoldsFisher Scientific22-363-553
Microtome blades, low
profile
Fisher Scientific12-634-1C
Optimal Cutting
Temperature (OCT)
medium
VWR75806-668
CryostatThermo Scientific14-071-401

List of antibodies.

See Table 9.

Table 9. Summary of antibodies used.

AntibodiesSupplierCatalogue No.
Tyrosine Hydroxylase (TH),
rabbit, polyclonal
Pel FreezP40101-150
β-Tubilin III (TUJ1), mouse,
monoclonal
MilliporeMAB5564
MAP2, chicken, polyclonalEnCor
Biotechnology
CPCA-MAP2
Donkey anti-chicken Alexa 488Jackson
ImmunoResearch
703-545-155
Donkey anti-mouse Dylight 550Abcamab96876
Donkey anti-rabbit Dylight 650Abcamab96894

Method

Protocol description for iPSC culture and maintenance

General principles for culturing and maintaining human iPSCs. Human iPSCs are sensitive to many stresses, including shear stress, heat shock, and changes in media formulation and must be manipulated with extreme care at all steps of the protocol.

Technical and safety considerations for manipulating IPSCs

  • The iPSC cells should not have been passaged more than 10 times.

  • The cells need to be a minimum of passage 2 after thawing for generation of midbrain organoids.

  • Do not work with colonies that present with differentiated areas (Figure 1a). We recommend removing the differentiated areas during daily maintenance and to never exceed 5% of differentiated areas prior to organoid generation for optimal organoid formation.

  • Sterile technique must be used at all times when working with cells or in preparing reagents and materials.

  • Human iPSCs lines are to be handled within a Class II biosafety laminar flow hood to protect the worker from possible biohazardous agents.

ba98022f-b8e9-46cc-a6e0-e949dbe8c514_figure1.gif

Figure 1. Midbrain organoid generation, timeline and steps of tissue formation.

a) Quality of iPSCs suitable for midbrain organoids formation. b) Timeline for midbrain organoid generation. PBMCs (peripheral blood mononuclear cells) from individuals were collected and reprogrammed into iPSCs. Uniform embryoids bodies are formed from iPSC colonies and then patterned into neuronal midbrain fate with inductive signals. EBs are then embedded in Matrigel scaffold to promote growth of tissue. The tissue formed was cultured on an orbital shaker for several months. c) EB with smooth edge 48 hours after formation. d) Extrusion of buds on EB after midbrain patterning. e) Typical EB 24 hour after embedding in Matrigel®. f) Day 1, 5 and 15 after transferring the tissue into final differentiation media. Scale bar= 500 μm.

Preparing Matrigel® hESC-qualified matrix coated culture dishes, thawing frozen human iPSCs cryovials, and daily maintenance of human iPSCs

  • Start by thawing an aliquot of 150-200 µl Matrigel® hESC-qualified Matrix at 4°C, 15–20 minutes prior to use (depends on the dilution factor of each lot per manufacturer instructions).

  • Prepare DMEM/F-12 solution by removing 5 mL of DMEM/F-12 from a 500 mL bottle and adding 5 mL of anti-anti. Place the bottle at 4°C until cold.

  • Once the Matrigel® is thawed and DMEM/F-12 is cold, prepare a coating solution diluted as per manufacturer instructions and mix well.

  • Immediately use the diluted Matrigel® solution to evenly coat the tissue culture dishes (2 ml/ 60 mm dish and 5 ml/ 100mm dish) by swirling the tissue culture dish in each direction, multiple times. Incubate at 37°C for a minimum of one hour before use.

  • Meanwhile, warm up mTeSRTM 1 and DMEM/F-12 medium at room temperature (RT) for a minimum of one hour. Do not use a water bath during this process because the media components would be degraded.

  • Once the tissue culture dish is coated and mTeSRTM 1 and DMEM/F-12 medium are warmed, get the frozen cryovial of iPSCs from the liquid nitrogen storage container, and quickly thaw the vial by warming in a 37°C water bath. Continuously shake the cryovial until only a small frozen pellet remains.

  • Using a 5 mL glass pipette, transfer the contents of the cryovial to a 5 mL solution of DMEM-F12 (with anti-anti), in dropwise manner and gently pipette up and down 1–2 times.

  • Centrifuge the cells at 1200 rpm for 3 minutes at RT. After centrifugation, aspirate the medium, leaving the cell pellet intact. Using a 5 mL glass pipette, gently resuspend (1–2 times) the cell pellet in 3 mL of mTeSRTM 1 medium containing Y27632 (1:1000 dilution).

  • Take the coated tissue culture dish from 37°C and aspirate out the coating medium. Transfer the cells in mTeSRTM 1 medium to the coated dish and place in a 37°C, 5% CO2 incubator. Do not disturb the dish for 24h, to allow the cells to attach.

  • Change the medium every day with mTeSRTM 1 without Y27632, until the cell confluency reaches 70% and cells are close in contact.

  • Daily, visually identify regions of differentiation under the microscope and remove them by aspiration under the sterile hood.

Passaging of human iPSCs

  • When the cells reach 60-70% confluency, they are ready to be split.

  • Aspirate out the medium from the dish and wash the cells with 3 mL DMEM/F-12 (with anti-anti).

  • Add gentle cell dissociation medium (5 ml for 100 mm dish and 1 mL for 60 mm dish) at RT until the cells at the edge of the colony begin to detach from each other. (Note: Do not leave cells for longer as the cell viability will be affected)

  • Aspirate out the gentle cell dissociation medium from the dish and wash the dish with DMEM/F-12.

  • Add 5mL DMEM/F-12 to the dish and gently detach the colonies by scrapping with a cell scrapper. Using a glass pipette, transfer the detached cell aggregates in a Falcon tube.

  • Centrifuge the Falcon tube with cells at 1200 rpm for 3 minutes.

  • After the centrifugation is done, check the pellet and aspirate out the supernatant (do not let the pellet dry so leave 100 μL-200 μl DMEM after aspiration).

  • Using a glass pipette, resuspend the pellet gently to break the cell aggregates in mTeSRTM 1 medium with 10μM Y27632.

  • For seeding cells, add 10% of the original cell suspension to a new coated dish when passaging between similar size dishes. For a small to large dish passage-take 20% of the original cell suspension and from a large to small dish, take 5%.

  • Incubate the dishes at 37°C until the colonies reach 70% confluency.

Generating midbrain organoids

Eight days are necessary to generate midbrain organoids from iPSC colonies. Then, the organoids are grown with constant agitation for maturation. The timeline is described in Figure 1b.

Seeding of iPSCs – Day 0

  • Start with one 10 cm dish of iPSCs at 70% confluency, cultured in mTeSRTM 1 to obtain 96 midbrain organoids from a 96-well ultra-low attachment plate.

  • Dissociate cells using Accutase by removing medium from cells, wash cells once with DMEM-F12 +Anti-Anti and add 5 ml Accutase at RT. Incubate cells for 3 minutes at 37°C, then stop reaction with DMEM-F12+Anti-Anti. Transfer the medium with the cells into a 15 mL Falcon tube and centrifuge for 3 min, at 1200 rpm in a regular Falcon centrifuge. Remove the supernatant.

  • Using a 1mL tip combined with a 200 µl tip resuspend cells in 5 ml of neuronal induction medium (Table 3) by pipetting gently up and down 3 times. Count cells. Note: The 200 µl tip is at the end of the 1 ml tip.

  • Plate 10,000 cells/well in an ultra-low attachment 96 well U-bottomed plate with a multichannel pipette and add neuronal induction medium (Table 3) to a total of 200 µl/well with a multichannel pipette.

  • Centrifuge the plate for 10 min at 1200 rpm at 37°C.

  • Incubate cells for 48 hrs at 37°C in a regular cell incubator.

Change medium – Day 2

Observation: EBs should have smooth and round edges (Figure 1c)

  • Change medium to neuronal induction medium WITHOUT ROCK inhibitor using a multichannel pipette.

  • Incubate cells for 48 hrs at 37°C in a regular cell incubator.

Change medium – Day 4

Observation: EBs should reach a diameter of >300 µm (typically 400-600 µm) with smooth and round edges

  • Change medium to midbrain patterning medium (Table 4) using a multichannel pipette.

  • Incubate cells for 48 hrs at 37°C in regular cell incubator.

Change medium and embedding in Matrigel® – Day 7

Observation: Neuroectoderm buds should have started to extrude before the embedding (Figure 1d)

  • Transfer aliquots of Matrigel® reduced growth factors to ice and let it reach 4°C.

  • Remove the medium from each well with a multichannel pipette and add 30 µl of reduced growth factor Matrigel® with the manual repeater-pipette and sterile distritips.

  • Incubate the plate for 30 min at 37°C in a regular cell incubator.

  • Add 200 µl of tissue growth induction medium (Table 5) and incubate for 24 hours at 37°C in a regular cell incubator.

  • Autoclave a box of 1mL cut tips if not already done.

Transfer the organoids to final differentiation medium – Day 8

Observations: Neuroepithelium should be more developed (Figure 1e)

  • Add 3 mL of final differentiation medium per well of an ULTRA LOW ATTACHMENT 6 well plate.

  • Transfer the midbrain organoids with a cut 1000 µl pipette tip into the 6 well plate (5 organoids/well).

  • Put the 6 well plates on the orbital shaker (set at 70 rpm) in the 37°C regular cell incubator and change the medium every 2–3 days using final differentiation medium (Table 6). When the midbrain organoids reach 1 mm in diameter, increase the final differentiation media volume to 5 mL to provide enough nutrients (Figure 1f).

Observations: From day 1 in final differentiation media to day 50 the organoids should grow from 600 μm to approximately 4 mm (Figure 2). The presence of dopaminergic neurons is tested by immunofluorescence staining with tyrosine hydroxylase antibody (Figure 3a–c). In parallel, the functionality of dopaminergic neurons is tested at 35 days by treating the midbrain organoids with 100 μm of dopamine. The appearance of black/brown dots after 10 days correspond to neuromelanin granules, a by-product of dopamine synthesis (Figure 4).

ba98022f-b8e9-46cc-a6e0-e949dbe8c514_figure2.gif

Figure 2. Difference in size expected from day 1 to day 50 in final differentiation media.

The hMOs will grow from 600μm to 4mm. Scale bar= 4mm.

ba98022f-b8e9-46cc-a6e0-e949dbe8c514_figure3.gif

Figure 3. Typical cytoarchitecture of hMOs at day 30.

a) Cryosection of hMO. The immunofluorescence staining for tyrosine hydroxylase reveals dopaminergic neurons (red) and nuclei (blue). We observe multiple ventricule-like structures or “rosettes”. b) A typical rosette in hMOs is composed of neural progenitor cells (squares) and differentiated cells (triangles). On the outside layer of the rosette, we observe the dopaminergic neurons stained with anti-tyrosine hydroxylase TH (red), and the neurons stained for MAP2 (green) and TUJ1 (yellow) (stars). The cells negative for MAP2, TH and TUJ1 are progenitors (squares). Scale bar=200μm. c) Higher magnification of differentiated neurons. We observe the presence of dopaminergic neurons revealed by TH staining. Scale bar = 70μm.

Histological processing of organoids by cryosectioning

Tissue fixation and cryoprotection

  • Remove medium from plates and fix organoids with submersion in fresh 4% formaldehyde solution for 1h at RT or O/N at 4°C in fume hood.

    HAZARD WARNING: Use care handling formaldehyde solutions. Follow instructions according to the product MSDS.

  • Wash organoids with PBS 3 times for 5 min to remove formaldehyde.

  • Incubate organoids in 20% sucrose solution at 4°C until the organoids sink. This is usually achieved O/N or after 3 days.

    NOTE: Do not extend the incubation for longer than 3 days, as this impacts the quality of sectioning. In rare occasions, the tissue does not sink after a long time because it includes low-density components such as Matrigel®. However, this does not impact subsequent procedures.

Block embedding

  • Transfer organoids from the sucrose solution to a cryomold using a pipette with a cut tip. We typically embed up to 9 organoids per block. If embedding different types of organoids (different ages, cell lines, etc.) in the same block, care must be taken not to mix the organoids.

  • After all organoids are placed in the mold, remove all the sucrose solution with a paper tissue, taking care that the organoids do not stick to the paper.

  • Slowly pour optimal cutting temperature (OCT) mounting medium directly on top of the organoids to ensure they stay on the bottom of the cryomold. If embedding different types of organoids, be careful to maintain their organization.

  • Use a needle to place organoids in the desired positions, while taking care not to move organoids upwards. Space the organoids about 1 mm from each other.

  • Freeze organoids by placing the mold in a -80°C freezer or in the gaseous phase of a liquid N2 container. When moving the mold, take care not to tilt excessively, which may displace the organoids.

  • Once completely frozen, blocks may be stored long term inside a closed container to prevent drying in a -80°C freezer.

Cryosectioning

  • Set cryostat temperature and place all blocks to be cut in the same session inside the cryostat chamber to equilibrate the temperature.

  • NOTE: The relationship between the cryostat temperature and the actual temperature at the block surface after mounting varies according to the cryostat model. Using a thermal probe, we found that a surface temperature of -9°C allows easy production of high-quality samples. However, the precise setting necessary to achieve this temperature must be determined for each machine.

  • Prior to, or shortly after, removal of the block from mold, cut one corner of the block to keep track of the block orientation in the subsequent steps.

  • Trim the block edges using a razor blade, maintaining a margin of 1-2 mm of OCT around the area containing organoids.

    WARNING: Use care when handling the razor blade inside of the cryostat. Avoid manually cutting blocks that are not equilibrated with the cryostat temperature, as these become harder and need more strength to be cut, which may lead to injuries.

  • Pour an amount of OCT on the sample holder (chuck) sufficient to cover the entire bottom surface of the block.

  • Press the block on top of the OCT layer on the sample holder using a heat extractor to orient the block as horizontally as possible. Wait until OCT freezes completely.

  • Place the mounted block in the microtome head and cut sections in the desired thickness. We routinely produce sections with a thickness ranging between 10 and 20 µm.

  • If necessary, flatten sections using a pair of brushes and pick sections using a slide kept at room temperature (direct mount method).

  • Let slides air dry for 30–60 min and proceed with histological staining. The slides may also be kept in boxes at -80°C for long term storage.

    Observations: Cryosections on 30-day aged midbrain organoids reveal the presence of rosettes in the tissue (Figure 3a). The progenitors are localized in the center of rosettes while the more mature neurons localized on the external layer. The differentiated cells are positive for neuronal markers such as MAP2 and TUJ1. TH is more specific for dopaminergic neurons (Figure 3bc).

Immunostainings, images acquisition and statistical analysis

Immunostaining and Fontana Masson staining. Cryosections were rehydrated in PBS for 15 min and surrounded with a hydrophobic barrier using a barrier pen. The sections were then blocked for one hour at room temperature in a humidified chamber, with blocking solution (5% of normal donkey serum, 0.05% BSA, and 0.2%Triton X-100 in PBS. They are then incubated overnight at 4°C with primary antibodies diluted in blocking solution (See Table 9). The following day, cryosections were washed three times in PBS, fifteen minutes each, and then incubated in secondary antibodies diluted in blocking solution (See Table 9) for one hour at room temperature. Then we washed the sections three times in PBS for fifteen minutes each. Hoerscht (diluted 1/5000 in PBS) was incubated 10 min on sections, followed by a wash in PBS for 10 min. Finally, we mounted the section with an aqua-mounting media and visualized the staining under a confocal microscope (Figure 3).

Fontana Masson stainings (Figure 4b) were performed with an Abcam staining kit (#ab150669) following provider’s instructions on regular paraffin sections of hMos.

ba98022f-b8e9-46cc-a6e0-e949dbe8c514_figure4.gif

Figure 4. Dopaminergic neurons release by-products of dopamine synthesis.

a) At day 35 in final differentiation media, midbrain organoids are treated with 100 μm dopamine for 10 days. Under dopamine treatment, brown/black areas appeared. b) Fontana Masson staining confirmed the presence of neuromelanin granules with dopamine treatment. Black dots are extracted with colorimetric selection from GIMP software and quantified by ImageJ (ref. (63)). c) Statistical analysis of neuromelanin granules number in GraphPad Prism, unpaired t-test, p*** <0.001, 4n.

Imaging. iPSCs colonies (Figure 1a) were imaged with an inverted microscope Motic AE2000 and the Moticam BTO camera associated, while the EBs images (Figure 1c–f) were taken with a transmitted light microscope EVOS XL Core. The hMos (Figure 2 and Figure 4a) were imaged with a ZEISS Stemi 508 stereomicroscope combined with a ZEISS Axiocam ERc 5s camera. The fluorescence images (Figure 3) were acquired with a Leica TCS SP8 confocal. Fontana Masson stainings (Figure 4b) were acquired with a clinical microscope Olympus BX46 and an Olympus DP27 digital color camera associated.

Raw fluorescent images were opened in ImageJ software (version 2.0.0-rc-69/1.52i) with a red, blue, green or yellow color associated to each channel, before all images were merged to create a merged image. Black dots from Fontana Masson stainings pictures were extracted with colorimetric selection from GIMP software (version 2.8.22) and quantified by ImageJ (version 2.0.0-rc-69/1.52i) following the method described in 63.

Statistical analysis. The statistical analysis was performed in GraphPad Prism v7.0. For the quantification of neuromelanin granules, we performed a normality test followed by a parametric unpaired t-test, p***<0.001.

Results and observations

We observed that good quality of iPSCs is determinant to successfully generate high-quality of hMOs. iPSCs colonies are maintained daily and passaged in order to present no differentiated area (Figure 1a). If the colonies still presented less than 5% of differentiated areas after the precautions described, we removed the differentiated areas prior to the generation of hMOs to ensure an optimal quality of hMOs. The process to generate hMOs from iPSCs, at 70% confluency, takes eight days (Figure 1b). Then, embryoid bodies formed from the iPSCs, were differentiated toward midbrain fate in stationary culture and embedded in Matrigel® to promote the formation of the tissue. Indeed, we observed the progressive appearance of the tissue within the EB (Figure 1c–f). Once the EBs presented multiple bud extrusion (Figure 1e), they were transferred to shaking culture to promote the growth of the tissue (Figure 1b and 1f). After 50 days of shaking culture in final differentiation media, the hMOs grew up to approximately four millimeters (Figure 2).

Immunostainings on cryosections of hMOs thirty days-aged, showed a typical cytoarchitecture (Figure 3a) with multiple rosettes. The center of the rosettes was composed of neural progenitors cells, negative for MAP2 and TUJ1 (Figure 3b squares) while the outside layer is composed of more matured cells, including neurons MAP2 positive (Figure 3b arrows and stars). As expected for hMos, we detected the presence of tyrosine hydroxylase (TH) cells (Figure 3c). Finally, to test the functionality of the dopaminergic neurons, we treated hMos at day 35 with dopamine. We observed the appearance of brown/black areas, suspected to be neuromelanin granules accumulations, also known as by-products of dopamine synthesis (Figure 4a)36. Silver stains were showed to bind to neuromelanin granules in the substantia nigra64. Thus, we confirmed the presence of neuromelanin granules in hMOs by Fontana Masson staining (Figure 4b) and observed a significant increase of neuromelanin granules after dopamine treatment (Figure 4b–c). Raw images and data are available as Underlying data65.

Concluding remarks

In our group, we have successfully generated hMBOs from patient-derived iPSCs. However, there are various challenges that are associated with the generation of organoids. (i) iPSC lines are very sensitive and require delicate culture techniques to avoid differentiation. This can be achieved by choosing a range of iPSC passage number suitable for generating good EBs. (ii) Batch-to-batch reproducibility is difficult to achieve. It can be controlled by optimizing chemical and physical parameters of media and incubation. (iii) Optimal concentrations of components in the media need to be carefully chosen. There are various chemical factors that contribute to the generation of organoids, and therefore require careful standardization. (iv) Generation of uniform EBs, is the key factor in the generation of organoids. Uniform, smooth and continuous edges of EBs are essential to develop uniform organoids. (v) The speed of the shaker is crucial in the final differentiation of organoids and maintaining 3D organization. (vi) Cryosectioning organoids is a challenging analysis step. Since the organoids form a structure distinct from that of natural tissue, some protocol adaptations were necessary to consistently generate high quality sections. Furthermore, due to tissue organization and small sizes, sections have to be optimized for each stage of organoid maturation. Other methods such as clearing techniques can be useful to overcome this challenge. So far, we have overcome the challenges and generated numerous high-quality midbrain organoids. It is important to note that the quality of the iPSCs remains the most crucial step in the formation of organoid tissue.

Data availability

Underlying data

Open Science Framework: Generation of human midbrain organoids from induced pluripotent stem cells. https://doi.org/10.17605/OSF.IO/GF39H65

This project contains the following underlying data:

  • Figure 1a iPSC colonies.jpg (Quality of iPSCs suitable for midbrain organoids formation.)

  • Figure 1c EB with smooth edge 48 hours after formation.jpg (EB with smooth edge 48 hours after formation in neuronal induction media.)

  • Figure 1d Extrusion of buds on EB after midbrain patterning.jpg (Extrusion of buds on EB after midbrain patterning.)

  • Figure 1e Typical EB 24 hours after embedding in matrigel.jpg (Typical EB 24 hours after embedding in Matrigel®.)

  • Figure 1f Day 15 after transferring the tissue into final differentiation media.jpg (Typical hMo at day 15 after transferring the tissue into final differentiation media.)

  • Figure 1f Day 1 after transferring the tissue into final differentiation media.jpg (Typical hMo at day 1 after transferring the tissue into final differentiation media.)

  • Figure 1f Day 5 after transferring the tissue into final differentiation media.jpg (Typical hMo at day 5 after transferring the tissue into final differentiation media.)

  • Figure 2 Day 1 in final differentiation media.jpg (At day 1 in final differentiation media, hMOs are approximately 600μm.)

  • Figure 2 Day 50 in final differentiation media.jpg (At day 50 in final differentiation media, hMOs are approximately 4mm.)

  • Figure 3a Cryosection of hMO.tif (Cryosection of hMO at day 30. The immunofluorescence staining reveals dopaminergic neurons and multiple ventricule-like structures or “rosettes”.)

  • Figure 3b map2.tif (MAP2 staining reveals the presence of neurons on the outside layer of rosettes.)

  • Figure 3b nuclei.tif (Nuclei staining of the section.)

  • Figure 3b th.tif (TH staining reveals the presence of dopaminergic neurons on the outside layer of rosettes.)

  • Figure 3b tuj1.tif (TUJ1 staining reveals the presence of neurons on the outside layer of rosettes.)

  • Figure 3c map2.tif (MAP2 staining reveals the presence of neurons.)

  • Figure 3c nuclei.tif (Nuclei staining of the section.)

  • Figure 3c th.tif (TH staining reveals the presence of dopaminergic neurons.)

  • Figure 3c tuj1.tif (TUJ1 staining reveals the presence of neurons.)

  • Figure 4a 45 days hMO with dopamine treatment.JPG (Under dopamine treatment, brown/black areas appeared in hMos.)

  • Figure 4a 45 days hMO without dopamine treatment.JPG (hMos, not treated with dopamine, are used as controls.)

  • Figure 4b colorimetric extraction on 45 days hMO with dopamine treatment.jpeg (Colorimetric selection from GIMP software on hMos treated with dopamine.)

  • Figure 4b colorimetric extraction on 45 days hMO without dopamine treatment.jpeg (Colorimetric selection from GIMP software on control hMos not treated with dopamine.)

  • Figure 4b fontana masson on 45 days hMO with dopamine treatment.TIF (Fontana Masson staining on hMo treated with dopamine.)

  • Figure 4b fontana masson on 45 days hMO without dopamine treatment.TIF (Fontana Masson staining on hMo not treated with dopamine.)

Author details Author details
Competing interests
Grant information
Copyright
Download
 
Export To
metrics
VIEWS
$counts.viewCount
 
downloads
Citations
CITE
how to cite this article
Mohamed NV, Mathur M, da Silva RV et al. Generation of human midbrain organoids from induced pluripotent stem cells [version 1; peer review: 1 approved, 3 approved with reservations] MNI Open Res 2019, 3:1 (https://doi.org/10.12688/mniopenres.12816.1)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.

Open Peer Review

Current Reviewer Status: ?
Key to Reviewer Statuses VIEW
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
Version 1
VERSION 1
PUBLISHED 03 Apr 2019
Views
0
Cite
Reviewer Report 07 May 2019
Birgitt Schuele, Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA 
Approved with Reservations
VIEWS 0
In this review Mohamed et al. describe a protocol and cryosectioning method for midbrain organoids from human IPSCs. The basis of this protocol is a combination of three previously published organoid methods by Lancaster 2013, Jo 2016, and Monzel 2017.
... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Schuele B. Reviewer Report For: Generation of human midbrain organoids from induced pluripotent stem cells [version 1; peer review: 1 approved, 3 approved with reservations]. MNI Open Res 2019, 3:1 (https://doi.org/10.21956/mniopenres.13879.r26158)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
  • Author Response 11 Feb 2021
    nguyen-vi mohamed, Montreal Neurological Institute and Hospital, Montreal, Canada
    11 Feb 2021
    Author Response
    • It is important to advance protocols for robust differentiation into 3D cultures. Overall, it is a comprehensive and detailed protocol. The manuscript is lacking is a section on
    ... Continue reading
COMMENTS ON THIS REPORT
  • Author Response 11 Feb 2021
    nguyen-vi mohamed, Montreal Neurological Institute and Hospital, Montreal, Canada
    11 Feb 2021
    Author Response
    • It is important to advance protocols for robust differentiation into 3D cultures. Overall, it is a comprehensive and detailed protocol. The manuscript is lacking is a section on
    ... Continue reading
Views
0
Cite
Reviewer Report 23 Apr 2019
Mark E. Hester, Center for Perinatal Research, The Research Institute at Nationwide Children's Hospital, Columbus, OH, USA 
Approved
VIEWS 0
Mohamed et. al. describes an optimized protocol to generate human midbrain organoids derived from human iPSCs. In this article, the authors utilize multiple hiPSC lines and optimize chemical and physical parameters of media formulations and incubation times to achieve a ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Hester ME. Reviewer Report For: Generation of human midbrain organoids from induced pluripotent stem cells [version 1; peer review: 1 approved, 3 approved with reservations]. MNI Open Res 2019, 3:1 (https://doi.org/10.21956/mniopenres.13879.r26159)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
  • Author Response 11 Feb 2021
    nguyen-vi mohamed, Montreal Neurological Institute and Hospital, Montreal, Canada
    11 Feb 2021
    Author Response
    Mohamed et. al. describes an optimized protocol to generate human midbrain organoids derived from human iPSCs. In this article, the authors utilize multiple hiPSC lines and optimize chemical and physical ... Continue reading
COMMENTS ON THIS REPORT
  • Author Response 11 Feb 2021
    nguyen-vi mohamed, Montreal Neurological Institute and Hospital, Montreal, Canada
    11 Feb 2021
    Author Response
    Mohamed et. al. describes an optimized protocol to generate human midbrain organoids derived from human iPSCs. In this article, the authors utilize multiple hiPSC lines and optimize chemical and physical ... Continue reading
Views
0
Cite
Reviewer Report 18 Apr 2019
Olga Corti, Brain and Spine Institute (ICM), Paris, France 
Philippe Ravassard, Brain and Spine Institute (ICM), Paris, France 
Approved with Reservations
VIEWS 0
The manuscript by Nguyen-Vi Mohamed and colleagues describes a standardized procedure for the generation and characterization of midbrain organoids from human iPSC lines, developed by adapting and integrating key reference protocols in the field. The production of such organoids is ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Corti O and Ravassard P. Reviewer Report For: Generation of human midbrain organoids from induced pluripotent stem cells [version 1; peer review: 1 approved, 3 approved with reservations]. MNI Open Res 2019, 3:1 (https://doi.org/10.21956/mniopenres.13879.r26157)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
  • Author Response 11 Feb 2021
    nguyen-vi mohamed, Montreal Neurological Institute and Hospital, Montreal, Canada
    11 Feb 2021
    Author Response
    The manuscript by Nguyen-Vi Mohamed and colleagues describes a standardized procedure for the generation and characterization of midbrain organoids from human iPSC lines, developed by adapting and integrating key reference ... Continue reading
COMMENTS ON THIS REPORT
  • Author Response 11 Feb 2021
    nguyen-vi mohamed, Montreal Neurological Institute and Hospital, Montreal, Canada
    11 Feb 2021
    Author Response
    The manuscript by Nguyen-Vi Mohamed and colleagues describes a standardized procedure for the generation and characterization of midbrain organoids from human iPSC lines, developed by adapting and integrating key reference ... Continue reading
Views
0
Cite
Reviewer Report 11 Apr 2019
Scott D. Ryan, Department of Molecular and Cellular Biology, University of Guelph (U of G), Guelph, ON, Canada 
Approved with Reservations
VIEWS 0
In this manuscript Nguyen et al. present a protocol for derivation of human midbrain organoids from induced pluripotent stem cells. This paper integrates recent advances in the field stemming from work pioneered by Lancaster and advanced by both Jo et ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Ryan SD. Reviewer Report For: Generation of human midbrain organoids from induced pluripotent stem cells [version 1; peer review: 1 approved, 3 approved with reservations]. MNI Open Res 2019, 3:1 (https://doi.org/10.21956/mniopenres.13879.r26160)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
  • Author Response 11 Feb 2021
    nguyen-vi mohamed, Montreal Neurological Institute and Hospital, Montreal, Canada
    11 Feb 2021
    Author Response
    In this manuscript Nguyen et al. present a protocol for derivation of human midbrain organoids from induced pluripotent stem cells. This paper integrates recent advances in the field stemming from ... Continue reading
COMMENTS ON THIS REPORT
  • Author Response 11 Feb 2021
    nguyen-vi mohamed, Montreal Neurological Institute and Hospital, Montreal, Canada
    11 Feb 2021
    Author Response
    In this manuscript Nguyen et al. present a protocol for derivation of human midbrain organoids from induced pluripotent stem cells. This paper integrates recent advances in the field stemming from ... Continue reading
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Sign In
If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

The email address should be the one you originally registered with F1000.

Email address not valid, please try again

You registered with F1000 via Google, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Google account password, please click here.

You registered with F1000 via Facebook, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Facebook account password, please click here.

Code not correct, please try again
Email us for further assistance.
Server error, please try again.